EMERGENT BIOSOLUTIONS INC. — Income Charts
12 quarters of history · ending 2026-03-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-29.7% -$66M
$156M
Cost of Revenue↓-18.6% -$17M
$72M
Gross Profit↑+84.9% +$74M
$161M
R&D↓-30.5% -$5M
$11M
SG&A↓-11.1% -$6M
$47M
D&A↓-7.5% -$2M
$24M
Operating Income↓-79.0% -$39M
$11M
EBITDA↓-54.8% -$41M
$34M
Interest Expense↓-25.2% -$4M
$11M
Interest Income
—
Other Income/Expense↓-75.8% -$44M
$14M
Pretax Income↓-85.5% -$79M
$13M
Tax Provision↓-73.3% -$18M
$7M
Net Income↓-90.0% -$61M
$7M
Gross Margin↑+22.6pts
54.9%
Operating Margin↓-15.7pts
6.7%
Net Margin↓-26.2pts
4.4%
Effective Tax Rate↑+22.6pts
49.3%
Deferred Tax Assets
—
Deferred Tax Liabilities↓-44.9% -$27M
$33M
DTA Valuation Allowance↓-2.9% -$9M
$310M
ETR (Continuing Operations)↑+69.5pts
36.5%
ETR Federal Statutory
21.0%
Operating Lease Cost↑+0.0% +$0
$200K
Pension Net Periodic Cost
$0
Revenue YoY Variation↓-3.7pts
-29.7%
Income YoY Variation↓-104.3pts
-79.0%
Revenue QoQ Variation↓-9.1pts
5.0%
Income QoQ Variation↑+4549.6pts
4681.3%